G101SPM Posted - 04/11/24

#INSIDERS $CRMT President & CEO bought 3,229 shares at $60.28 - $62.00 worth approx. $199K. $TRDA Director bought 2600 shares at $13.49 - $13.78 worth ~$35K. $GTX 10% owner sold 330,195 shares at $9.95 - $10.01 worth ~$3.3 mln.

insiderbuyingselling Posted - 04/10/24

$TRDA new insider buying: 2600 shares. http://insiderbuyingselling.com/?t=TRDA

maizeblue22 Posted - 4 weeks ago

$TRDA the modular endosomal escape technology is a major asset. I’m surprised more people aren’t looking at this company. If nothing else, betting on a versatile platform like this can make for a solid long position

insiderbuyingselling Posted - 1 month ago

$TRDA new insider buying: 1512 shares. http://insiderbuyingselling.com/?t=TRDA

G101SPM Posted - 03/27/24

#INSIDERS $GO Director bought 36,500 shares at $28.14 - $28.2495 worth ~$1.03 mln. $LEGH Director bought 5,050 shares at $19.83 - $19.90 worth ~$100K. $RC Director bought 9,150 shares at $9.11 - $9.13 worth ~$83K. $TRDA Director bought 9,048 shares at $13.22 - $13.80 worth ~$123K. $AME Director sold 780 shares at $182.00 worth ~$142K.

insiderbuyingselling Posted - 03/26/24

$TRDA new insider buying: 9048 shares. http://insiderbuyingselling.com/?t=TRDA

valueforme Posted - 03/14/24

$TRDA "Vertex Pharmaceuticals announced it received clearances from Health Canada and Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom for Clinical Trial Applications for VX-670 for patients with myotonic dystrophy type 1 (DM1). Vertex initiated the Phase 1/2 clinical trial in patients with DM1 in Canada and will initiate the study in the UK near-term. "

DonCorleone77 Posted - 03/13/24

$TRDA Entrada Therapeutics expects cash to fund requirements through 2Q26 Cash, cash equivalents and marketable securities were $352.0 million as of December 31, 2023, compared to $188.7 million as of December 31, 2022. This increase was primarily due to the proceeds received to date from the Vertex Agreement. Entrada anticipates that its cash, cash equivalents and marketable securities as of December 31, 2023, together with ongoing research support and the anticipated achievement of certain milestones pursuant to the Vertex collaboration, will be sufficient to fund the Company's operating expenses and capital expenditure requirements through the second quarter of 2026.

DonCorleone77 Posted - 03/13/24

$TRDA Entrada Therapeutics reports Q4 EPS (29c), consensus (17c) Reports Q4 revenue $41.8M, consensus $23.69M. "We continue to make significant progress advancing our growing pipeline of intracellular therapeutics," said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. "We have an exciting year ahead in 2024, with several important clinical milestones within our Duchenne franchise, including the expected fourth quarter submissions of Phase 2 regulatory applications for the global development of ENTR-601-44 and ENTR-601-45. Clinical momentum is also building in our collaboration with Vertex, with the initiation of a Phase 1/2 clinical trial of VX-670 in patients with DM1. With the extension of our cash runway through the second quarter of 2026, we believe we are well positioned to progress our Duchenne franchise and broader pipeline to create value for patients and shareholders."

Stock_Titan Posted - 03/13/24

$TRDA Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/TRDA/entrada-therapeutics-reports-fourth-quarter-and-full-year-2023-wt5ftqecqsv1.html

valueforme Posted - 03/10/24

$rna and $dyn - similar indications, similar approaches to address them, similar stock price appreciation recently. Who else is the neurology oligonucleotide race but has no attention from retail at all? $TRDA is one of them. DM1 program is partnered to Vertex and is currently in Phase 1. DMD programs - one in phase 1, several more preclinical. Delivery tech is completely different from RNA and DYN.

insiderbuyingselling Posted - 03/08/24

$TRDA new insider selling: 4086 shares. http://insiderbuyingselling.com/?t=TRDA

valueforme Posted - 03/08/24

$TRDA Foundational paper summarizing the delivery tech https://pubs.acs.org/doi/10.1021/bi5004102#

valueforme Posted - 03/04/24

$TRDA Started position here after several rounds of DD. Still need to dig deeper to understand endosomal escape science, but business wise the setup is looking good . Fireside chat with the CEO at the Oppenheimer conf is helpful to understand the current situation https://wsw.com/webcast/oppenheimer33/trda/2770486

Ninja_Tradez Posted - 1 month ago

Don's forget to check Calendar: https://www.tradershub.ninja/calendar $TRDA $CRT $OBIO $KRNL Never Miss any alert 🚨Check Discord Link 🔗 on bio

valueforme Posted - 02/29/24

$TRDA No one here. Perfect.

TickerDD_com Posted - 02/26/24

From 2/13/2024, looking back across 22 Month-Ends for TRDA, Percentage Change of Average Monthly Price had More Positives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $TRDA #TRDA #TRDAStock #TickerDD #TRDAPrice https://www.youtube.com/watch?v=HaZiu6XvIwE

Bugseason Posted - 02/16/24

$TRDA damn looks like all insiders are selling

Stock_Titan Posted - 02/07/24

$TRDA Entrada Therapeutics to Present at Upcoming Investor Conferences https://www.stocktitan.net/news/TRDA/entrada-therapeutics-to-present-at-upcoming-investor-3plwipb3loe1.html

TipRanks Posted - 01/29/24

‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks https://www.tipranks.com/news/article/time-to-pull-the-trigger-says-oppenheimer-about-these-3-stocks $BFH $TRDA $COIN

tickeron Posted - 01/20/24

The market looks weird..Do not be too greedy today! $TRDA in Downtrend: Stochastic indicator leaves overbought zone. View odds for this and other indicators: https://srnk.us/go/4973822

MarketBeatInsiderTrades Posted - 01/18/24

Entrada Therapeutics CEO Dipal Doshi Sells $15,990.00 in $TRDA www.marketbeat.com/stocks/NASDAQ/TRDA/insider-trades/

cctranscripts Posted - 01/18/24

Entrada Therapeutics, Inc.'s CEO just disposed of 1,000 shares https://www.conferencecalltranscripts.org/summary/?id=12877112 $TRDA

risenhoover Posted - 01/18/24

Insider Dipal Doshi reports selling 1,000 shares of $TRDA for a total cost of $15,990.00 https://fintel.io/n/us/trda/doshi-dipal?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider

StockAutomatePro Posted - 01/09/24

$TRDA The chart shows the stock may be headed for a boost. We alerted the BUY signal at $14.61 and we were able to close this one with profit at $17 🎲

StockAutomatePro Posted - 01/09/24

$TRDA Looks like the stock may experience a surge chart analysis confirms. We alerted the BUY signal at $14.6 and we were able to close this one with profit at $15.8🤙

cctranscripts Posted - 3 months ago

Entrada Therapeutics Promotes Nathan J. Dowden To President https://www.conferencecalltranscripts.org/summary/?id=12836956 $TRDA

Last10K Posted - 3 months ago

$TRDA just filed with the SEC a Event for Officers and a Financial Exhibit https://last10k.com/sec-filings/TRDA/0001104659-24-000571.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=TRDA

risenhoover Posted - 3 months ago

$TRDA / Entrada Therapeutics files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 ENTRADA THERAPE https://fintel.io/doc/sec-entrada-therapeutics-inc-1689375-8k-2024-january-03-19725-6503?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

Stock_Titan Posted - 4 months ago

$TRDA Entrada Therapeutics Promotes Nathan J. Dowden to President https://www.stocktitan.net/news/TRDA/entrada-therapeutics-promotes-nathan-j-dowden-to-9cqy817onp22.html